Literature DB >> 26865668

Estimating Margin of Exposure to Thyroid Peroxidase Inhibitors Using High-Throughput in vitro Data, High-Throughput Exposure Modeling, and Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling.

Jeremy A Leonard1, Yu-Mei Tan2, Mary Gilbert3, Kristin Isaacs2, Hisham El-Masri4.   

Abstract

Some pharmaceuticals and environmental chemicals bind the thyroid peroxidase (TPO) enzyme and disrupt thyroid hormone production. The potential for TPO inhibition is a function of both the binding affinity and concentration of the chemical within the thyroid gland. The former can be determined through in vitro assays, and the latter is influenced by pharmacokinetic properties, along with environmental exposure levels. In this study, a physiologically based pharmacokinetic (PBPK) model was integrated with a pharmacodynamic (PD) model to establish internal doses capable of inhibiting TPO in relation to external exposure levels predicted through exposure modeling. The PBPK/PD model was evaluated using published serum or thyroid gland chemical concentrations or circulating thyroxine (T4) and triiodothyronine (T3) hormone levels measured in rats and humans. After evaluation, the model was used to estimate human equivalent intake doses resulting in reduction of T4 and T3 levels by 10% (ED10) for 6 chemicals of varying TPO-inhibiting potencies. These chemicals were methimazole, 6-propylthiouracil, resorcinol, benzophenone-2, 2-mercaptobenzothiazole, and triclosan. Margin of exposure values were estimated for these chemicals using the ED10 and predicted population exposure levels for females of child-bearing age. The modeling approach presented here revealed that examining hazard or exposure alone when prioritizing chemicals for risk assessment may be insufficient, and that consideration of pharmacokinetic properties is warranted. This approach also provides a mechanism for integrating in vitro data, pharmacokinetic properties, and exposure levels predicted through high-throughput means when interpreting adverse outcome pathways based on biological responses. Published by Oxford University Press on behalf of the Society of Toxicology 2016. This work is written by US Government employees and is in the public domain in the US.

Entities:  

Keywords:  PBPK/PD model; adverse outcome pathway; high-throughput in vitro assay.; margin of exposure; thyroid peroxidase

Mesh:

Substances:

Year:  2016        PMID: 26865668      PMCID: PMC4914794          DOI: 10.1093/toxsci/kfw022

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  56 in total

Review 1.  Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment.

Authors:  Gerald T Ankley; Richard S Bennett; Russell J Erickson; Dale J Hoff; Michael W Hornung; Rodney D Johnson; David R Mount; John W Nichols; Christine L Russom; Patricia K Schmieder; Jose A Serrrano; Joseph E Tietge; Daniel L Villeneuve
Journal:  Environ Toxicol Chem       Date:  2010-03       Impact factor: 3.742

2.  The acclumulation of 35 S-antithyroid drugs by the thyroid gland.

Authors:  B Marchant; W D Alexander; J H Lazarus; J Lees; D H Clark
Journal:  J Clin Endocrinol Metab       Date:  1972-05       Impact factor: 5.958

3.  The pharmacokinetics of propylthiouracil.

Authors:  J Kampmann; L Skovsted
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1974-11

4.  Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man.

Authors:  J T Nicoloff; J C Low; J H Dussault; D A Fisher
Journal:  J Clin Invest       Date:  1972-03       Impact factor: 14.808

5.  Metabolic clearance and production rates of human thyrotropin.

Authors:  E C Ridgway; B D Weintraub; F Maloof
Journal:  J Clin Invest       Date:  1974-03       Impact factor: 14.808

6.  Pharmacokinetics of methimazole in humans.

Authors:  J H Hengstmann; H Hohn
Journal:  Klin Wochenschr       Date:  1985-12-02

7.  The pharmacokinetics of methimazole after oral administration of carbimazole and methimazole, in hyperthyroid patients.

Authors:  G G Skellern; B I Knight; C K Low; W D Alexander; D G McLarty; W J Kalk
Journal:  Br J Clin Pharmacol       Date:  1980-02       Impact factor: 4.335

8.  Propylthiouracil inhibits the conversion of L-thyroxine to L-triiodothyronine. An explanation of the antithyroxine effect of propylthiouracil and evidence supporting the concept that triiodothyronine is the active thyroid hormone.

Authors:  J H Oppenheimer; H L Schwartz; M I Surks
Journal:  J Clin Invest       Date:  1972-09       Impact factor: 14.808

9.  SHEDS-HT: an integrated probabilistic exposure model for prioritizing exposures to chemicals with near-field and dietary sources.

Authors:  Kristin K Isaacs; W Graham Glen; Peter Egeghy; Michael-Rock Goldsmith; Luther Smith; Daniel Vallero; Raina Brooks; Christopher M Grulke; Halûk Özkaynak
Journal:  Environ Sci Technol       Date:  2014-10-21       Impact factor: 9.028

Review 10.  Estimating xenobiotic half-lives in humans from rat data: influence of log P.

Authors:  J G Sarver; D White; P Erhardt; K Bachmann
Journal:  Environ Health Perspect       Date:  1997-11       Impact factor: 9.031

View more
  8 in total

1.  Aggregate Exposure Pathways in Support of Risk Assessment.

Authors:  Yu-Mei Tan; Jeremy A Leonard; Stephen Edwards; Justin Teeguarden; Alicia Paini; Peter Egeghy
Journal:  Curr Opin Toxicol       Date:  2018-03-29

Review 2.  IVIVE: Facilitating the Use of In Vitro Toxicity Data in Risk Assessment and Decision Making.

Authors:  Xiaoqing Chang; Yu-Mei Tan; David G Allen; Shannon Bell; Paul C Brown; Lauren Browning; Patricia Ceger; Jeffery Gearhart; Pertti J Hakkinen; Shruti V Kabadi; Nicole C Kleinstreuer; Annie Lumen; Joanna Matheson; Alicia Paini; Heather A Pangburn; Elijah J Petersen; Emily N Reinke; Alexandre J S Ribeiro; Nisha Sipes; Lisa M Sweeney; John F Wambaugh; Ronald Wange; Barbara A Wetmore; Moiz Mumtaz
Journal:  Toxics       Date:  2022-05-01

Review 3.  Challenges Associated With Applying Physiologically Based Pharmacokinetic Modeling for Public Health Decision-Making.

Authors:  Yu-Mei Tan; Rachel R Worley; Jeremy A Leonard; Jeffrey W Fisher
Journal:  Toxicol Sci       Date:  2018-04-01       Impact factor: 4.849

4.  The GOLIATH Project: Towards an Internationally Harmonised Approach for Testing Metabolism Disrupting Compounds.

Authors:  Juliette Legler; Daniel Zalko; Fabien Jourdan; Miriam Jacobs; Bernard Fromenty; Patrick Balaguer; William Bourguet; Vesna Munic Kos; Angel Nadal; Claire Beausoleil; Susana Cristobal; Sylvie Remy; Sibylle Ermler; Luigi Margiotta-Casaluci; Julian L Griffin; Bruce Blumberg; Christophe Chesné; Sebastian Hoffmann; Patrik L Andersson; Jorke H Kamstra
Journal:  Int J Mol Sci       Date:  2020-05-14       Impact factor: 5.923

Review 5.  Intrathyroidal feedforward and feedback network regulating thyroid hormone synthesis and secretion.

Authors:  Li Jing; Qiang Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-15       Impact factor: 6.055

6.  Mechanistic Computational Model for Extrapolating In Vitro Thyroid Peroxidase (TPO) Inhibition Data to Predict Serum Thyroid Hormone Levels in Rats.

Authors:  Sakshi Handa; Iman Hassan; Mary Gilbert; Hisham El-Masri
Journal:  Toxicol Sci       Date:  2021-08-30       Impact factor: 4.109

Review 7.  Bridging the Data Gap From in vitro Toxicity Testing to Chemical Safety Assessment Through Computational Modeling.

Authors:  Qiang Zhang; Jin Li; Alistair Middleton; Sudin Bhattacharya; Rory B Conolly
Journal:  Front Public Health       Date:  2018-09-11

8.  Mechanism of Action and Interactions between Thyroid Peroxidase and Lipoxygenase Inhibitors Derived from Plant Sources.

Authors:  Ewa Habza-Kowalska; Urszula Gawlik-Dziki; Dariusz Dziki
Journal:  Biomolecules       Date:  2019-10-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.